The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results ...

Opens in a new tab or window Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) inhibitors, offer a new treatment paradigm ...

Largest long-term data set of any FcRn blocker in gMG shows sustained ... therapies for patients with gMG shows that Fc receptor blockers, particularly VYVGART, show a more favorable benefit ...

In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 ...

Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profileof VYVGART and VYVGART HytrulogMG patients on VYVGART ...